table of content
1 Introduction to Research & Analysis Reports
1.1 Adeno-Associated Virus Vectors in Gene Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adeno-Associated Virus Vectors in Gene Therapy Overall Market Size
2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size: 2022 VS 2029
2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales: 2018-2029
3 Company Landscape
3.1 Top Adeno-Associated Virus Vectors in Gene Therapy Players in Global Market
3.2 Top Global Adeno-Associated Virus Vectors in Gene Therapy Companies Ranked by Revenue
3.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Companies
3.4 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Companies
3.5 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Adeno-Associated Virus Vectors in Gene Therapy Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Adeno-Associated Virus Vectors in Gene Therapy Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adeno-Associated Virus Vectors in Gene Therapy Players in Global Market
3.8.1 List of Global Tier 1 Adeno-Associated Virus Vectors in Gene Therapy Companies
3.8.2 List of Global Tier 2 and Tier 3 Adeno-Associated Virus Vectors in Gene Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Market Size Markets, 2022 & 2029
4.1.2 Serotype 2 (AVV 2)
4.1.3 Synthetic Serotypes
4.1.4 Others
4.2 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue & Forecasts
4.2.1 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2023
4.2.2 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2024-2029
4.2.3 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share, 2018-2029
4.3 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Sales & Forecasts
4.3.1 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2023
4.3.2 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2024-2029
4.3.3 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share, 2018-2029
4.4 By Type - Global Adeno-Associated Virus Vectors in Gene Therapy Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2022 & 2029
5.1.2 Alzheimer's Disease
5.1.3 Cystic Dibrosis
5.1.4 Hemophilia B
5.1.5 Parkinson's Disease
5.2 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue & Forecasts
5.2.1 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2023
5.2.2 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2024-2029
5.2.3 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share, 2018-2029
5.3 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Sales & Forecasts
5.3.1 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2023
5.3.2 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2024-2029
5.3.3 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share, 2018-2029
5.4 By Application - Global Adeno-Associated Virus Vectors in Gene Therapy Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2022 & 2029
6.2 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue & Forecasts
6.2.1 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2023
6.2.2 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2024-2029
6.2.3 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share, 2018-2029
6.3 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Sales & Forecasts
6.3.1 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2023
6.3.2 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Sales, 2024-2029
6.3.3 By Region - Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2029
6.4.2 By Country - North America Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2029
6.4.3 US Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.4.4 Canada Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.4.5 Mexico Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2029
6.5.2 By Country - Europe Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2029
6.5.3 Germany Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.4 France Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.5 U.K. Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.6 Italy Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.7 Russia Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.8 Nordic Countries Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.5.9 Benelux Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2029
6.6.2 By Region - Asia Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2029
6.6.3 China Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.6.4 Japan Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.6.5 South Korea Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.6.6 Southeast Asia Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.6.7 India Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2029
6.7.2 By Country - South America Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2029
6.7.3 Brazil Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.7.4 Argentina Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Sales, 2018-2029
6.8.3 Turkey Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.8.4 Israel Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.8.5 Saudi Arabia Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
6.8.6 UAE Adeno-Associated Virus Vectors in Gene Therapy Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amicus Therapeutics
7.1.1 Amicus Therapeutics Company Summary
7.1.2 Amicus Therapeutics Business Overview
7.1.3 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.1.4 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.1.5 Amicus Therapeutics Key News & Latest Developments
7.2 Asklepios Biopharmaceutical
7.2.1 Asklepios Biopharmaceutical Company Summary
7.2.2 Asklepios Biopharmaceutical Business Overview
7.2.3 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.2.4 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.2.5 Asklepios Biopharmaceutical Key News & Latest Developments
7.3 BioMarin Pharmaceutical
7.3.1 BioMarin Pharmaceutical Company Summary
7.3.2 BioMarin Pharmaceutical Business Overview
7.3.3 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.3.4 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.3.5 BioMarin Pharmaceutical Key News & Latest Developments
7.4 Coave Therapeutics
7.4.1 Coave Therapeutics Company Summary
7.4.2 Coave Therapeutics Business Overview
7.4.3 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.4.4 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.4.5 Coave Therapeutics Key News & Latest Developments
7.5 MeiraGTx
7.5.1 MeiraGTx Company Summary
7.5.2 MeiraGTx Business Overview
7.5.3 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.5.4 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.5.5 MeiraGTx Key News & Latest Developments
7.6 Neurocrine Biosciences
7.6.1 Neurocrine Biosciences Company Summary
7.6.2 Neurocrine Biosciences Business Overview
7.6.3 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.6.4 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.6.5 Neurocrine Biosciences Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.7.4 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer Key News & Latest Developments
7.8 Roche Holding
7.8.1 Roche Holding Company Summary
7.8.2 Roche Holding Business Overview
7.8.3 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.8.4 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.8.5 Roche Holding Key News & Latest Developments
7.9 Sangamo Therapeutics
7.9.1 Sangamo Therapeutics Company Summary
7.9.2 Sangamo Therapeutics Business Overview
7.9.3 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.9.4 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.9.5 Sangamo Therapeutics Key News & Latest Developments
7.10 Sarepta Therapeutics
7.10.1 Sarepta Therapeutics Company Summary
7.10.2 Sarepta Therapeutics Business Overview
7.10.3 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.10.4 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.10.5 Sarepta Therapeutics Key News & Latest Developments
7.11 Spark Therapeutics
7.11.1 Spark Therapeutics Company Summary
7.11.2 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Business Overview
7.11.3 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.11.4 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.11.5 Spark Therapeutics Key News & Latest Developments
7.12 Voyager Therapeutics
7.12.1 Voyager Therapeutics Company Summary
7.12.2 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Business Overview
7.12.3 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.12.4 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.12.5 Voyager Therapeutics Key News & Latest Developments
7.13 NightstaRx
7.13.1 NightstaRx Company Summary
7.13.2 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Business Overview
7.13.3 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Major Product Offerings
7.13.4 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales and Revenue in Global (2018-2023)
7.13.5 NightstaRx Key News & Latest Developments
8 Global Adeno-Associated Virus Vectors in Gene Therapy Production Capacity, Analysis
8.1 Global Adeno-Associated Virus Vectors in Gene Therapy Production Capacity, 2018-2029
8.2 Adeno-Associated Virus Vectors in Gene Therapy Production Capacity of Key Manufacturers in Global Market
8.3 Global Adeno-Associated Virus Vectors in Gene Therapy Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Adeno-Associated Virus Vectors in Gene Therapy Supply Chain Analysis
10.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Value Chain
10.2 Adeno-Associated Virus Vectors in Gene Therapy Upstream Market
10.3 Adeno-Associated Virus Vectors in Gene Therapy Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Adeno-Associated Virus Vectors in Gene Therapy Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
